REPLICor to present preclinical data showing a curative response to hepatitis B infection with its drug at the 1^st Annual Girindus Leaders in Oligonucletides Meeting

Laval, Quebec – March 31, 2009 -- Dr. Andrew Vaillant, VP, Operations and Chief Scientific Officer, has been invited to present REPLICor’s latest preclinical data on the use of its drug for the treatment of hepatitis B.  This presentation will include the latest data from REPLICor’s collaboration with the lab of Dr. Allison Jilbert and will demonstrate for the first time the achievement of a curative response to hepatitis B infection in a preclinical animal model using REPLICOR’s drug.